Trial Profile
A Phase III Randomized, Double-Blind Trial of Chemoembolization With or Without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients With and Without Vascular Invasion
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Cisplatin; Doxorubicin; Mitomycin
- Indications Liver cancer
- Focus Therapeutic Use
- 15 Nov 2023 Status changed from active, no longer recruiting to completed.
- 14 Jan 2021 Planned primary completion date changed from 15 Dec 2020 to 29 Jan 2021.
- 18 Sep 2020 Planned primary completion date changed from 1 Sep 2020 to 15 Dec 2020.